Analyst Rating Update on Immunomedics (IMMU)

Immunomedics (NASDAQ:IMMU) : 2 analysts are covering Immunomedics (NASDAQ:IMMU) and their average rating on the stock is 2, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Wells Fargo downgrades its ratings on Immunomedics (NASDAQ:IMMU). According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on June 21, 2016.

Immunomedics (NASDAQ:IMMU): stock turned positive on Tuesday. Though the stock opened at $2.18, the bulls momentum made the stock top out at $2.23 level for the day. The stock recorded a low of $2.05 and closed the trading day at $2.18, in the green by 9.00%. The total traded volume for the day was 2,013,814. The stock had closed at $2 in the previous days trading.

In an insider trading activity, Goldenberg David M, director officer (CSO & Chairman of the BOD) of Immunomedics Inc, unloaded 371,990 shares at an average price of $3.04 on June 10, 2016. The total amount of the transaction was worth $1,130,850, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *